At NINGBO INNO PHARMCHEM CO.,LTD., we are driven by scientific curiosity and a commitment to advancing healthcare. Our latest research in oncology focuses on a promising new class of drugs: SN38-glucose conjugates. These innovative compounds are designed to revolutionize the treatment of cancers like colorectal cancer by harnessing a fundamental characteristic of malignant cells – their heightened demand for glucose.

The scientific foundation of our work is rooted in the observation of the Warburg effect, a metabolic anomaly where cancer cells prioritize glycolysis even in the presence of oxygen, leading to increased glucose uptake. This is often mediated by the overexpression of glucose transporters (GLUTs) on the surface of cancer cells. NINGBO INNO PHARMCHEM CO.,LTD. has developed a sophisticated strategy to exploit this vulnerability by creating SN38-glucose conjugates. This approach embodies the principles of glucose transporter targeted drug delivery, ensuring that the potent cytotoxic agent SN38 is delivered more precisely to tumor sites.

Our R&D efforts have led to the synthesis of various SN38-glucose conjugates. One particular compound, identified as 5b, has shown exceptional promise in preclinical evaluations. In laboratory settings, it demonstrates potent antiproliferative effects on colorectal cancer cell lines and has proven effective in inhibiting tumor growth in animal models. The mechanism involves not only the targeted delivery of SN38 but also its ability to induce cancer cell apoptosis and hinder cell migration, crucial steps in controlling cancer progression. This highlights the efficacy of our novel SN38 glucose conjugates targeting cancer cells.

The development of truly effective anticancer agents for CRC treatment requires innovative thinking and robust scientific validation. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing these cutting-edge solutions. Our work in novel anticancer compound synthesis aims to produce therapies that are not only more potent but also safer for patients. The focus on selective chemotherapy for colorectal cancer ensures that we are creating treatments that offer a better balance between efficacy and tolerability.

We are committed to supplying the scientific and pharmaceutical communities with high-quality materials to support further research and development. NINGBO INNO PHARMCHEM CO.,LTD. offers a range of pharmaceutical intermediates and APIs that meet stringent quality standards. Our ongoing contributions to preclinical oncology drug development are a testament to our dedication to combating cancer through scientific innovation.

We invite you to partner with NINGBO INNO PHARMCHEM CO.,LTD. to explore the scientific advancements in targeted cancer therapies. Together, we can push the boundaries of what is possible in medicine and bring hope to patients worldwide.